In the second part of our interview with Fadi Haddad, MD, an assistant professor and co-leader of the Section of Chronic ...

In an interview with Targeted Oncology at the 2025 ASH Annual Meeting & Exposition, Mitul Gandhi, MD, medical oncologist, ...

The primary end point of the study, major molecular response at 12 months, was achieved by 69% of patients. Approximately a ...

During a live event, Jan Drappatz, MD, surveyed participants on the rationale for their choice of treatment for a 39-year-old patient with grade 2 astrocytoma.

Crucially, the analysis demonstrated that less invasive procedures like TAD/SLNB/TLNB are noninferior to ALND in terms of axillary recurrence based on the lower bound of a 90% confidence interval ...

Initial breast surgery was initial BCS in 91.2% of the MRI arm and 92.7% of the no MRI arm; axillary surgery was sentinel lymph node biopsy alone in 86.4% and 94.7%, respectively; final margin status ...

Sacituzumab govitecan maintained physical functioning scores, contrasting with chemotherapy's deterioration in advanced TNBC patients. Time to deterioration in fatigue was comparable between ...

Factors associated with higher progression rates included double-hit/triple-hit lymphoma, high IPI status, and primary refractory disease. A recent study reveals critical insights on disease ...

A phase 1/2 clinical trial examining the CRISPR-engineered allogeneic chimeric antigen receptor (CAR)-T candidate AVC-203 (QUADvance) has been approved by the FDA and the European Medicines Agency ...

Abemaciclib monotherapy benefited 33% of patients with HR-positive, HER2-negative breast cancer post-CDK4/6 inhibitor progression. Abemaciclib shows promise as a monotherapy for HR-positive, ...

Tucatinib addition to trastuzumab and pertuzumab significantly improved PFS in HER2-positive metastatic breast cancer, with a median PFS of 24.9 months versus 16.3 months with placebo. The PFS benefit ...

The ACCESS trial shows mismatched unrelated donors can provide excellent outcomes, addressing racial disparities in donor ...